Jun 10, 2020
International Atherosclerosis Society Issues Call to Action to Improve Lipid Management Based on Survey Results to Address Patients' Residual Risk
Mar 28, 2020
Novartis new analysis further showed durable and potent LDL-C reduction with inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment
Mar 28, 2020
Amgen Announces Positive Results At ACC.20/WCC From Phase 3B Study Of Repatha® (Evolocumab) In People Living With HIV Who Have High LDL-Cholesterol
Mar 18, 2020
Novartis announces NEJM publication of three pivotal trials showing durable and potent efficacy of inclisiran, an investigational first-in-class siRNA cholesterol-lowering therapy
Feb 28, 2020
Are We Doing Enough To Protect Our Hearts?: Millions Of Patients Face Continued Cardiovascular Risk
Feb 19, 2020
Kowa Achieves Goal Of Randomizing 10,000 Patients Into Landmark "PROMINENT" Cardiovascular Outcomes Study Of K-877 (Pemafibrate)
Feb 06, 2020
Survivors in Canada are Taking Steps to Reduce the Risk of Another Heart Attack. But is it Enough?
Jan 09, 2020
MYOS CEO Joseph Mannello Issues Letter to Shareholders
Dec 03, 2019
AI Helps Find Signs of Heart Disease on Lung Cancer Screens
Nov 19, 2019
Viking Therapeutics Announces Initiation of Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
Nov 15, 2019
Amgen And The Duke Clinical Research Institute Announce Initiation Of First Large-Scale Registry To Evaluate Real-World Lipid Management And The Effectiveness Of PCSK9 Inhibitors
Nov 11, 2019
Amgen Highlights Data To Be Presented At AHA 2019 Across Cardiovascular Portfolio
Oct 24, 2019
Amgen To Make Repatha® (evolocumab) Available Exclusively At Its Lower List Price Option In 2020
Oct 23, 2019
Duke Clinical Research Institute to Lead Pragmatic Study to Assess Effectiveness of Statins in Older Adults
Sep 30, 2019
Medicure Announces Acquisition Of Full United States Ownership Of Zypitamag(TM)
Sep 17, 2019
Familial Hypercholesterolemia Patients at High Risk for Cardiovascular Events Despite Treatment
Aug 28, 2019
New Amgen Data To Be Presented At ESC Congress 2019 Highlight Additional Evidence For Repatha® (Evolocumab) Effectiveness In Cardiovascular Disease Across Multiple Patient Groups
Aug 14, 2019
Regeneron Announces Positive Topline Results from Phase 3 Trial of Evinacumab in Patients with Severe, Inherited Form of High Cholesterol
Jul 23, 2019
Individuals Had More Heart Attacks and Strokes When Cholesterol-lowering Drug Prescription Was Rejected or Unfilled
Mar 18, 2019
Vascepa® (icosapent ethyl) Showed 30% Reduction in Total Cardiovascular Events Including Recurrent Events in REDUCE-IT(TM)